Status:
NOT_YET_RECRUITING
STROKE 120 ACTION Trial
Lead Sponsor:
Shanghai Minhang Central Hospital
Conditions:
Ischemic Stroke
Eligibility:
All Genders
Phase:
NA
Brief Summary
Stroke is the main cause of death and disability in China, but it is preventable and treatable. For the most common type, acute ischemic stroke (AIS), initiating reperfusion therapy with intravenous t...
Eligibility Criteria
Inclusion
- This trial will evaluate whether the STROKE 120 multifaceted intervention campaign can reduce the pre-hospital delay in AIS and increase the 4.5-hour arrival rate in 16 community units across 8 regions in China. We will select 2 community units from each region as the study sites and randomly divide the 2 community units within each region into the intervention group and the control group. The selection criteria for community units are listed as follows:
- The 2 participating community units in each region should each have a permanent population over 110,000 (people aged 60 years and above accounting for at least 15%), have similar demographic characteristics (e.g., age, gender, and education level), and have comparable local health policies (e.g., medical insurance policies, emergency system framework, stroke emergency map release, and stroke center quality control), economic levels, and public ability to recognize AIS.
- The participating hospitals in each community unit serve \>90% of AIS patients within the community unit, have a well-established stroke center, and have comparable standardized treatment capabilities for AIS (including 4.5-hour hospital arrival rate of AIS, rate of using 120 emergency ambulances after AIS, and rate of IVT after AIS).
- The participating communities are capable of implementing STROKE 120 multifaceted intervention campaign within its community unit.
- To avoid cross-contamination, the physical distance between any two community units exceeds 20 kilometers.
Exclusion
Key Trial Info
Start Date :
November 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2027
Estimated Enrollment :
1696000 Patients enrolled
Trial Details
Trial ID
NCT07135310
Start Date
November 1 2025
End Date
January 31 2027
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Minhang Central Hospital
Shanghai, China